Join
Live feed
·
INSIDERFilingvia Quantisnow
Relmada Therapeutics Inc. logo

Director Kelly Paul Edward bought $64,750 worth of shares (25,000 units at $2.59), increasing direct ownership by 13% to 212,295 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RLMD· Relmada Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLMD (Relmada Therapeutics Inc.) and more on Quantisnow.